GSK Plc is voluntarily recalling more than 593,000 Ventolin asthma inhalers from U.S. hospitals, pharmacies, retailers and wholesalers due to a defect that may cause them to deliver fewer doses of the medicine than indicated, the British drugmaker said on Tuesday.
The company said it had received an elevated number of product complaints about a bulging of the outside wrapper, indicating a leak of the propellant that delivers the medicine. The recall involves three lots of the Ventolin HFA 200D inhalers manufactured at GSK’s plant in Zebulon, North Carolina.